Welcome to CDC Stacks | Pneumococcal polysaccharide vaccine. - 7474 | Guidelines and Recommendations
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Filetype[HTML - ]
View this content


This is an HTML document so it cannot be previewed.
To open, click the "View" button.
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like:
  1. Pneumococcal polysaccharide vaccine
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.)
    Published:
    4/24/15
    Series:
    Vaccine information statement
    Description:
    1. Why get vaccinated? -- 2. Pneumococcal polysaccharide vaccine (PPSV23)– 3. Some people should not get this vaccine – 4. Risks of a vaccine reaction – 5. What if there is a serious reaction? – 6. How can I learn more? : ppv.pdf
    File Type:
    Filetype[PDF - 324.39 KB]
  2. Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease.
    Personal Author:
    Fiore, A. E.; Levine, O. S.; Elliott, J. A.; Facklam, R. R.; Butler, J. C.;
    Published:
    1999 Nov-Dec
    Source:
    Emerg Infect Dis. 5(6):828-831.
    Description:
    To estimate the effectiveness of pneumococcal polysaccharide vaccine, we serotyped isolates submitted to the Pneumococcal Sentinel Surveillance System from 1984 to 1996 from 48 vaccinated and 125 unvaccinated children 2 to 5 years of age. Effectivene...
    File Type:
    Filetype[PDF - 94.74 KB]
  3. Prevention of pneumococcal disease among infants and children; use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine : recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Personal Author:
    Nuorti, J. Pekka.; Whitney, Cynthia G.;
    Corporate Author:
    United States, Advisory Committee on Immunization Practices.; Centers for Disease Control and Prevention (U.S.); National Center for Immunization and Respiratory Diseases (U.S.), Division of Bacterial Diseases.;
    Published:
    December 10, 2010
    Series:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 59, no. RR-11
    Description:
    "On February 24, 2010, a 13-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., marketed by Pfizer Inc.]) was licensed by the Food and Drug Administration (FDA) for prevention of invasive pneum...
    File Type:
    Filetype[PDF - 569.96 KB]
  4. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Personal Author:
    Bennett, Nancy M.; Whitney, Cynthia G.; Moore, Matt.; Pilishvili, Tamara.; Dooling, Kathleen L.;
    Corporate Author:
    National Center for Immunization and Respiratory Diseases (U.S.); United States. Advisory Committee on Immunization Practices. Pneumococcal Work Group;
    Published:
    2012 Oct 12
    Description:
    MMWR. Morbidity and mortality weekly report 2012 Oct 12;61(40):816-9. : Reported by: Nancy M. Bennett, MD, Advisory Committee on Immunization Practices Pneumococcal Work Group. Cynthia G. Whitney, MD, Matt Moore, MD, Tamara Pilishvili, MPH, Respirato...
    Status:
    current
    File Type:
    Filetype[PDF - 91.23 KB]
  5. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions : recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Personal Author:
    Bennett, Nancy M.; Whitney, Cynthia G.; Moore, Matt.; Pilishvili, Tamara.; Dooling, Kathleen L.;
    Corporate Author:
    National Center for Immunization and Respiratory Diseases (U.S.); United States. Advisory Committee on Immunization Practices.;
    Published:
    2012 Oct 12
    Description:
    On June 20, 2012, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.) for adults aged ≥19 years w...
    Status:
    current
    File Type:
    Filetype[PDF - 91.23 KB]